Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 3, 1997, Pages 876-883

  Colao, Annamaria ^a   Di Sarno, Antonella ^a   Sarnacchiaro, Francesca ^a   Ferone, Diego ^a   Di Renzo, Gianfranco ^a   Merola, Bartolomeo ^a   Annunziato, Lucio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GALACTORRHEA; GONAD FUNCTION; HEADACHE; HUMAN; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SOMNOLENCE; TUMOR VOLUME; VERTIGO; VISUAL FIELD;

EID: 0031017930     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.3.3822     Document Type: Article

References (19)

1. Thorner MO, McNeilly AS, Hagan C, Besser GM. 1974 Long-term treatment of galactorrhea and hypogonadism with bromocriptine. Br Med J. 2:419-422.
2. Molitch ME, Elton RL, Blackwell RE, et al. 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentric study. J Clin Endocrinol Metab. 60:698-705.
3. Chiodini GP, Liuzzi A, Cozzi R, et al. 1981 Size reduction of macroprolactinomas bv bromocriptine or lisuride treatment. J Clin Endocrinol Metab. 53:737-743.
4. Colao A, Merola B, Sarnacchiaro F, et al. 1995 Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinoma. Horm Res. 44:222-228.
5. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetski J, Kuhn JM. 1991 Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin Endocrinol (Oxf). 34:25-29.
6. Razzaq R, O'Halloran DJ, Beardwell CG, Shalet SM. 1993 The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Horm Res. 39:218-222.
7. Brue T, Pellegrini I, Gunz G, et al. 1992 Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab. 74:577-584.
8. Pellegrini I, Rasolonjanahary R, Gunz G, et al. 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 69:500-509.
9. 3H)CV 205-502. Brain Res 440:123-128.
10. Merola B, Sarnacchiaro F, Colao A, et al. 1994 Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol. 8:175-181.
11. Ferrari C, Barbieri C, Caldara R, et al. 1986 Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab. 63:941-945.
12. Ciccarelli E, Giusti M, Miola A, et al. 1989 Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 69:725-728.
13. Ferrari C, Mattei A, Melis GB, et al. 1989 Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab. 68:2101-2106.
14. Webster J, Piscitelli G, Polli A, et al. 1992 Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinemia: a placebo controlled, double blind, multicentric study. Clin Endocrinol (Oxf). 37:534-541.
15. Webster J, Piscitelli G, Polli A, et al. 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 331:904-909.
16. Biller BMK, Molitch ME, Vance ML, et al. 1996 Treatment of prolactin-secreting macroadenoma with once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 81:2338-2343.
17. 3H]N-n-propylnorapomorphine. Eur J Pharmacol. 187:399-408.
18. Eguchi K, Kawamoto K, Uozumi T, Ito A, Kurisu K. 1995 In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr J. 42:153-161.
19. Eguchi K, Kawamoto K, Uozumi T, Ito A, Arita K, Kurisu K. 1995 Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr J. 42:162-168.